

Index

- abnormal misfolded protein, 152
 acantholytic squamous cell carcinoma
 angiosarcoma and, 26
 conventional squamous cell carcinoma and, 26
 sun exposed skin and, 25–6
 acanthosis, 179
 acinic cell carcinoma, 48, 70–1
 acquired encephalocele of middle ear, 172
 adenocarcinoma NOS, 46
 adenocarcinomas, 102
 adenoid cystic carcinoma, 42, 111
 high grade, 95
 solid adenoid cystic carcinoma, 109
 adenosquamous carcinoma (ASC), 23, 26, 102
 HPV and, 23–4
 adipose tissue, 155
 advanced rectal adenocarcinoma, 127
 aerodigestive tract, 70, 123
 AFS. *See* ameloblastic fibrosarcoma
 aggressive papillary tumor (APT), 170–1
 AL. *See* localised amyloidosis
 ALK immunoreactivity, 182
 alveolar rhabdomyosarcoma, 77, 103–5
 alveolar soft part sarcoma, 74
 amelanotic tumors, 92
 ameloblastic differentiation, 116
 ameloblastic fibroma, 116–17
 ameloblastic fibrosarcoma (AFS), 116–17
 ameloblastoma, 114
 amyloid A, 152
 amyloidosis, 152
 anastomosing epithelial strands, 114
 angiocentric infiltrate, 90
 angiofibroma, 128, 131
 angiosarcoma, 106
 benign mimics and, 28
 epithelioid angiosarcoma, 26
 metastatic oral angiosarcoma, 27
 of oral mucosa, 27
 radiation-induced oral angiosarcoma, 27
 vascular markers and, 28
 anterior cranial fossa, 140
 antro-choanal polyp, 128
 apocrine differentiation, 121
 apocrine features, 46
 apocrine secretion, 121
 apoptotic bodies, 117
 APT. *See* aggressive papillary tumor
 arytenoids, 152
 ASC. *See* adenosquamous carcinoma
 Aspergillosis, 180
 atypical CD56+ cytotoxic T cells, 5
 atypical cells, 69
 atypical glandular proliferation, 125
 atypical pleomorphic adenoma, 60–1
 autologous bone marrow transplantation, 97

 B cell proliferation, 5
 basaloid cells, 41–2, 110–11
 basal-suprabasal elements, 179–80
 basophilic intracellular amastigotes, 4–5
 β -catenin gene mutations, 132
 bcl-2, 136
 benign sinonasal proliferations, 119
 beta catenin positivity, 129
 bilateral polyps, 119
 biphenotypic sinonasal sarcoma, 128–9, 139, 142
 bland endothelium, 151
 BRAF mutations, 91
 brain tissue, 172
 breast carcinomas, 70, 103
 Brooke–Spiegler syndrome, 42
 buccal mucosa, 12
 calcification, 32, 79, 157, 164, 175, 177
 calponin, 32, 34, 95
 positive for, 95–6, 123
Candida, 179
 CaPA. *See* Carcinoma ex pleomorphic adenoma
 capillary lobular hemangioma, 132
 capillary vessels, 181
 carcinoembryonic antigen (CEA), 23
 carcinoma, 23–4, 28, 177
 Carcinoma ex pleomorphic adenoma (CaPA), 58–9
 carotid body, 160–1
 cartilage cells, 31, 124
 cartilage degeneration, 166
 cartilaginous metaplasia, 29, 31
 CD10, 69
 CD20, 86
 CD31, 25
 negative staining for, 26
 neoplastic cells and, 27
 positivity for, 174
 CD34, 136
 CD45, 72, 76, 103
 CD56, 86, 103–4
 CD57, 34
 CD68, 14
 CD99, 76
 membrane staining, 82
 positivity, 103
 CD117 positivity, 41
 CD138, 85
 CEA. *See* carcinoembryonic antigen
 cellular atypia, 31, 56
 cellular cartilaginous neoplasm, 175
 cellular proliferation with pigment deposition, 162
 cervical lymph nodes, 17, 66
 cholesterol crystal deposition, 168
 chondroblastic osteosarcoma, 165
 chondroblastoma, 163
 chondroid choristoma, 35
 chondroid lipoma, 29
 tongue and, 29
 chondroid matrix, 32–3
 chondromyxoid matrix, 29, 33
 chondrosarcoma (CS), 32
 grade 2, 32–3
 of larynx, 175–6
 choristoma, 157
 choroid plexus, 157–8
 chromatin, 108
 chromogranin, 72–3, 103
 chronic inflammation, 147
 ciliated columnar epithelium, 118
 ciliated epithelium, 120
 ciliated respiratory cells, 125
 ciliated respiratory epithelium, 106, 144
 ciliated respiratory type epithelium, 119
 clear cells, 67
 change, 67–8
 clear cell epithelial-myoeipithelial carcinoma, 70
 clear cell myoeipithelial carcinoma of parotid gland, 49–51
 clear cell myoeipithelial tumors, 70
 containing PAS positive cytoplasmic glycogen, 67
 hyalinizing clear cell carcinoma, 71
 metastatic clear cell renal cell carcinoma, 68
 clear cytoplasm, 36, 49, 95–6
 squamous epithelium with, 101
 clear vacuolated cytoplasm, 74
 CMV. *See* cytomegalovirus
 CNGCT. *See* congenital gingival non-neural granular cell tumor
 collagen matrix, 136
 collagen stroma, 132
 collagenous matrix, 128
 colonic epithelium, 125

Index

- colorectal adenocarcinoma, 125, 127
 columnar ciliated epithelium, 148
 comedonecrosis, 93
 common muscle actin, 74, 76
 congenital gingival non-neural granular cell tumor (CNGCT), 14–15
 congenital pleomorphic adenoma, 123–4
 Congo staining, 152–3
 corkscrew-shaped bacteria, 16
 corticosteroids, 1
 cranial cavity, 140
 cricoid cartilage, 175
 crush artifacts, 103
 CS. *See* chondrosarcoma
 CTNNB1, 134
 cuboidal cells, 121
 cuboidal ciliated epithelium, 148
 cuboidal epithelium, 157, 172
 Cutaneous Leishmaniasis, 6
 cylindrical cell carcinoma, 109
 cylindroma, 41–2
 cystic chondromalacia, 166–7
 cysts, dilation of, 121
 cytokeratin 5/6, 25, 43, 50, 108
 positivity for, 26
 squamous differentiation and, 26
 cytokeratin 7, 23, 127
 cytokeratin 8, 108–9
 cytokeratin 14, 32, 43
 cytokeratin 20, 72–3
 cytokeratin AE1/AE3, 82
 cytokeratins, 12, 27, 34–5, 49, 81–2
 negative, 104
 positive for, 123
 cytologic atypia, 19, 29, 60–1, 112, 125, 164–5
 hyaline cartilage and, 29
 PA with cytologic atypia of myoepithelial cells, 60–1
 cytological atypia, 112
 cytomegalovirus (CMV), 1
 coinfection with HSV, 2
 systemic CMV disease, 2

 delicate arborizing capillary vasculature, 131
 delphian lymph node, 39
 delphian lymph node metastasis, 39
 delphian prelaryngeal lymph node, 38
 densely collagenized background, 160
 dento-alveolar region, 147
 dermatomyositis, 1
 dermoid, 150, 156
 desmin, 34, 74, 100
 positivity, 101, 103–4
 partial, 138

 desmoid-type fibromatosis, 79
 desmoplastic small round cell tumor, 100
 desmoplastic stroma, 160–1
 diastase digestion, 67
 differentiated adenocarcinoma, 127
 diffuse mucinous change, 119
 diplopia, 127
 dysphagia, 21, 81, 151
 dysplasia, 19, 23–4, 110, 145, 177
 dysplastic squamous epithelium, 25

 E6, 23–4
 E7, 23–4
 EBV. *See* Epstein-Barr virus
 eccrine spiradenomas, 42
 ECT. *See* ectomesenchymal chondromyxoid tumor of the tongue
 ectatic vessels, 134, 136
 ectomesenchymal chondromyxoid tumor of the tongue (ECT), 34–5
 EGFR mutations, 145
 elongated amphophilic cytoplasm, 78
 EMA, 32, 34–5, 43
 positive for, 123
 embryonal rhabdomyosarcoma, 76–7, 97, 131
 embryonic cartilage, 31
 embryonic development, 114
 enchondroma, 33
 endothelial atypia, 28
 eosinophilic deposits, 153
 eosinophilic extracellular matrix, 177
 eosinophilic fibrillary matrix, 157
 eosinophilic secretions, 47–8, 120–1
 eosinophils, 119
 epistaxis, 101, 103, 118, 125
 intermittent, 132
 recurrent, 132
 epithelial cells, 29, 45, 49, 56, 112, 183
 atypical, 58, 62
 columnar, 113, 170
 cuboidal, 113, 170
 flattened, 121
 polygonal, 69
 squamous, 21
 epithelial component, 123–4
 epithelial dysplasia, 9
 epithelial proliferation, 45
 epithelial squamous cells, 1
 epithelial structures, 123
 epithelial-myoepithelial carcinoma, 43–4
 epithelial-myoepithelial proliferation, 43
 epithelioid angiosarcoma, 26
 epithelioid cells, 14, 177
 atypical, 27
 large, 74
 markedly atypical, 25
 epithelioid endothelial cells, 28
 epithelioid endothelial tumors, 28
 epithelioid
 hemangioendothelioma, 28
 epithelioid histiocytes, 5
 epithelioid macrophages, 162
 epithelium, 12–13, 86. *See also* squamous epithelium
 corkscrew-shaped bacteria in, 16
 hyperplastic, 13, 19
 respiratory, 103
 Epstein-Barr virus (EBV), 5, 65–6
 expression, 109
 Lymphoepithelial carcinoma and, 66
 NK T-cell lymphoma and, 90
 in situ hybridization for, 88–90, 95, 108
 Wegener's granulomatosis and, 90
 erythema, 17
 erythrocytes, 25–6, 168
 extravasated, 128, 173
 interspersed, 27
 intracytoplasmic lumina and, 27
 estrogen, 15
 ethmoid sinus, 101, 116
 Schwannoma of, 140–2
 ethmoid sinuses, 137
 ETV6 gene, 47
 Eustachian tube obstruction, 36–7
 Ewing's sarcoma, 77, 82, 100
 EWS gene, 81–2
 rearrangements, 35, 77, 95
 EWSR1 gene, 50
 exophytic lesion, 21
 exophytic papillary architecture, 21–2
 exophytic papillary squamous lesion, 21
 exophytic sinonasal papilloma, 144
 extracellular mucous production, 125
 extramedullary plasmacytoma, 84

 familial autosomal dominant cylindromatosis (FADC), 42
 fibrillary matrix, 172
 fibrocystic changes, 121
 fibroepithelial polyp, 151
 fibrolipoma, 29
 fibromyxoid stroma, 117
 fibrosarcoma, 79

 infantile, 79
 fibrosis, 54, 106
 fibrotic substitution, 166
 fibrous septa, 29
 fibrous stroma, 62
 fibrovascular septa, 99
 fine needle aspiration biopsy (FNAB), 43, 54
 fine needle aspiration cytologic exam, 32
 fine needle aspiration cytology, 62
 first branchial cleft cyst, type II, 159
 FISH. *See* fluorescent in situ hybridization
 FKHR gene, 76
 flexible fiberoptic examination, 123
 fluorescent in situ hybridization (FISH), 52–3, 81–2
 FNAB. *See* fine needle aspiration biopsy
 FOXO1 gene, 103
 frontal lobe, 141

 gastrointestinal adenocarcinoma, 125
 gastrointestinal tract, 70
 GCDFP15, 47
 GFAP. *See* glial fibrillary acidic protein
 giant cell granuloma, 163
 Giemsa stain, 4
 gingiva, 14, 27
 congenital gingival non-neural granular cell tumor, 14–15
 inferior gingiva, 76
 gland-like structures, 118
 epithelial component and, 123
 glandular hamartoma of larynx, 155–6
 glandular proliferations, 118
 glial cells, 157
 glial fibrillary acidic protein (GFAP), 32, 34–5, 65, 70
 diffuse immunoreactivity for, 158
 negative for, 123
 positivity for, 95
 glial heterotopia, 172
 glomangiopericytoma, 134
 neoplastic cells in, 137
 glottic plane, 175
 glottic-epiglottic plicae, 173
 gnathic tumor, 114
 goblet cells, 55
 granular cell Schwannoma, 15
 granular cell tumors, 12, 74
 granulation tissue-like morphology, 181–2
 granulocytes, 16, 89, 168
 granulomatosis with polyangiitis, 6
 Grocott silver stain, 16

Index

- hairy polyp (HP), 150
 hamartoma, 150
 head and neck squamous cell carcinomas (HNSCCs), 40
 hearing loss, 36–7
 hemangioma, 28
 hemorrhage vascular thrombosis, 106
 hemorrhagic changes, 106
 hepatitis C-infection, 8
 HER2, 61
 Herpes simplex virus (HSV), 1
 coinfection with CMV, 2
 commonality of, 1–2
 morphologic features of, 2
 heterogeneously hyperintense signal, 69
 heterotopic neuroglial tissue (HNGT), 157
 heterozygous deletion, 93
HEY1-NCOA2 fusion, 77
 HHV8, 28, 174
 high grade undifferentiated neoplasm, 91
 histiocytes, 5, 89
Histoplasma capsulatum, 6
 HIV. *See* human immunodeficiency virus
 HLA-DQ, 8
 HLA-DR. *See* Human Leukocyte Antigen - DR isotype
 HMB45, 72, 76, 91–2, 103
 HNGT. *See* heterotopic neuroglial tissue
 HNSCCs. *See* head and neck squamous cell carcinomas
 homozygous deletion, 93
 HP. *See* hairy polyp
 HPV. *See* human papilloma virus
 HSV. *See* Herpes simplex virus
 Huang, S. C., 139
 human immunodeficiency virus (HIV), 17, 86
 Human Leukocyte Antigen – DR isotype (HLA-DR), 8
 human papilloma virus (HPV), 10, 63, 94, 143
 ASC and, 23–4
 high risk, 21–2, 38, 40
 HPV-high risk type cocktail, 110–11
 HPV-related carcinoma with adenoid cystic-like features, 110–11
 HPV-related Multiphenotypic Sinonasal Carcinoma, 110
 multifocal oncogenic HPV infection of pharynx, 40
 PSCC and, 22
 in situ hybridization for, 95
 synchronous oropharyngeal HPV-related carcinoma, 39–40
 hyaline basement membrane, 118–19
 hyaline cartilage, 29, 164
 cytologic atypia and, 29
 mature, 29, 31
 hyaline collagen, 79
 hyaline eosinophilic matrix, 177
 hyaline globules, 28
 hyaline matrix, 41
 hyalinizing clear cell carcinoma, 71
 hydropic degeneration, 9
 hyoid bone, 32
 grade 2 chondrosarcoma of, 32–3
 hyperortho- and parakeratosis, 10
 hyperparathyroidism, 163
 hyperplastic epithelium, 13, 19, 168
 hyperplastic lymphoid tissue, 81
 hyperplastic surface epithelium, 179
 IDH2 mutations, 108
 immature basaloid cells, 22
 immature blastomatous tissue, 98
 immunoblasts, 86
 immunoreactivity, 22
 immunosuppression, 72
 inconspicuous nucleoli, 21–2
 infantile fibrosarcoma, 79
 inferior gingiva, 76
 infiltrative growth, 68
 inflammatory nasal polyp with stromal atypia, 106
 inflammatory polyp, 119, 131
 INI1, 93–4, 108
 SMARCB1 (INI-1)-deficient sinonasal carcinoma, 93–4
 interlaced thin-walled dilated capillary vessels, 136
 intestinal small cell carcinoma, 63
 intestinal-type adenocarcinoma, 118
 intestinal-type adenocarcinoma (mucinous variant), 125
 intracapsular carcinomas, 59
 intracellular amastigotes, 6
 intracellular mucous production, 125
 intracranial space, 140
 intracytoplasmic mucin, 23
 intracytoplasmic lumina, 27
 intraductal carcinoma, 45–6
 intraluminal mucin, 23
 invasion in carcinoma ex-PA, 59
 ischemia, 19
 isoenzyme analysis, 4
 jugulodigastric metastasis, 38
 Kaposi sarcoma, 28, 174
 kappa light chain, 84–5, 152–3
 keratin debris, 159
 keratin production, 101
 keratinocytes, 8
 Ki67 labeling index, 60–1, 183
 kidney carcinomas, 70
 kinetoplasts, 4–5
KIT mutations, 91
 Klestadt's cysts, 149
 lambda light chain, 84–5, 152–3
 lamina papyracea, 103
 lamina propria, 17, 152
 large cell carcinomas, 92
 large-cell neuroendocrine carcinoma of larynx, 183–4
 Laryngeal Candidiasis, 179–80
 laryngeal chondroma, 176
 laryngeal lumen, 173
 laryngeal mesenchymal neoplasm, 174
 laryngeal mucosa, 38, 177
 laryngeal spindle cell carcinoma with granulation tissue-like morphology, 181–2
 laryngeal squamous cell carcinoma, 39–40
 laryngectomy, 38
 larynx, 22, 152
 CS of, 175–6
 glandular hamartoma of, 155–6
 large-cell neuroendocrine carcinoma of, 183–4
 localised amyloidosis of larynx and pharynx, immunoglobulin light chain (AL) type, 152
 poorly differentiated carcinomas of, 184
 spindle cell carcinoma of larynx with osteosarcoma-like stroma, 177
 LEC. *See* lymphoepithelial carcinoma
 leiomyoma, 79
 leiomyosarcoma, 79
 Leishmania amastigotes, 4
 Leishmania DNA, 5–6
Leishmania infantum, 4–5
 leishmaniasis, 4–5
 lichenoid dysplasia, 9
 lipid laden macrophages, 140
 lipoblasts, 29
 lipoma. *See also* chondroid lipoma
 cartilaginous metaplasia and, 29, 31
 spindle cell, 29
 subtypes of, 29
 lipometaplasia, 29
 liquefactive degeneration, 8
 lobular architecture, 19
 lobular capillary hemangioma, 134
 localised amyloidosis of larynx and pharynx, immunoglobulin light chain (AL) type, 152
 low grade adenocarcinoma, 119
 low grade cribriform cytoadenocarcinoma, 45
 low grade sinonasal adenocarcinoma non intestinal type, 118
 SH and, 120
 low-grade chondrosarcoma, 165
 low-grade cribriform cystadenocarcinoma, 48
 low-grade salivary duct carcinoma, 45
 LP. *See* lymphangiomatous polyp
 lumina, 119
 lung carcinomas, 70
 lymph node, 52
 axillary, 72
 cervical lymph nodes, 17, 66
 delphian, 39
 delphian lymph node metastasis, 39
 delphian prelaryngeal, 38
 enlarged, 89
 inguinal, 72
 intraparotid, 53–4, 72
 metastasis, 39, 101
 metastatic deposit, 56
 neck, 72–3
 periparotid, 53
 regional, 56–7
 submandibular, 17
 lymphangiomatous polyp (LP), 151
 lymphocytes, 5, 16, 37, 89, 119, 128
 aggregates of, 151
 infiltrate of, 173, 181
 normal B lymphocytes, 86
 scattered, 17–18, 151
 small, 90
 lymphocytes-rich stroma, 36
 lymphocytic inflammatory infiltrate, 8, 10
 lymphoepithelial carcinoma (LEC), 65–6
 lymphoepithelial cysts, 53
 lymphoepithelial sialadenitis, 66
 lymphoepithelial-like carcinoma, 109
 lymphoid infiltrate, 65
 prominent, 68
 lymphoid stroma, 54
 lymphoma, 4, 77, 97
 large B cell lymphoma, 84
 malignant, 100
 natural killer (NK) T-cell lymphoma, nasal type, 5, 89–90

Index

- lymphoma (cont.)
 non-Hodgkin lymphoma (NHL), 88
 peripheral T-cell lymphomas, 5
 plasmablastic lymphoma (PL), 84, 86–8
 lymphomatoid granulomatosis, 5
 lymphoproliferative disorders, 5, 66
- macrophages
 infiltrate of, 181
 scattered, 17–18
 macroscopic ulceration, 69
 magnetic resonance imaging (MRI), 38, 97
 malignant mesenchymal spindle cell proliferation, 116
 malignant peripheral nerve sheath tumor, 139
 MAML3, 139
 mammary analogue secretory carcinoma (MASC), 46–8
 mast cells, 128
 mature adipocytes, 29, 31
 mature brain tissue, 172
 mature lipoma with cartilaginous metaplasia, 29
 maxillary sinus, 101, 110, 116, 147
 SCC of, 147–8
 verrucous carcinoma of, 143–4
 MC. *See* myoepithelial carcinoma
 MCCUP. *See* Merkel cell carcinoma of unknown primary origin
 MEC. *See* mucoepidermoid carcinoma
 medial rectal muscle, 103
 melanin pigment, 91
 melanoma, 28, 77, 105
 malignant, 100
 melanophages, 91
 Merkel cell carcinoma, 63
 Primary Merkel cell carcinoma, 72
 Merkel cell carcinoma of unknown primary origin (MCCUP), 72–3
 mesenchymal chondrosarcoma, 77
 mesenchymal component, 101, 117, 123–4
 mesenchymal neoplasms, 132
 metaplasia, 54
 metaplastic epithelium, 55
 metaplastic squamous epithelium, 54
 metastasis, 53
 metastatic carcinoma, 160–1
 metastatic clear cell renal cell carcinoma, 68
 of parotid gland, 70–1
 metastatic colorectal adenocarcinoma, 127
 metastatic disease, 70, 92
 metastatic nasopharyngeal nonkeratinizing undifferentiated carcinoma, 66
 metastatic oral angiosarcoma, 27
 metastatic oropharyngeal angiosarcoma, 27
 metastatic rectal adenocarcinoma, 127
 metastatic renal cell carcinoma, 70
 MIB1, 61, 86
 microcysts, 47
 microglandular adenosis of breast, 120
 middle cranial fossa, 132
 middle ear adenoma, 171
 midline polypoid oral lesion, 14
 mitotic activity, 28, 76, 78
 associated with fibromyxoid stroma, 117
 brisk, 86, 95, 108, 114, 116, 118, 123, 177
 focal areas of, 123
 high, 79, 183
 mitotic figures, 62, 117
 rare, 138
 mixed epithelial lining, 149
 ML. *See* mucosal leishmaniasis
 MNOH. *See* multifocal nodular oncocytic hyperplasia
 monoclonal antibodies, 4
 monoclonal B-cell population, 86
 monoclonal gammopathy, 84
 monolateral endonasal craniectomy, 141
 mononuclear histiocytoid cells, 162
 mononuclear inflammatory cells, 4–5
 monophasic synovial sarcoma, 139
 MRI. *See* magnetic resonance imaging
 MS. *See* myeloid sarcoma
 mucocele, 148
 mucocytes, 36
 mucoepidermoid carcinoma (MEC), 19, 24, 48, 53, 70, 121
 mucosa, 58, 86, 89
 aerodigestive tract covered by, 123
 buccal mucosa, 12
 intraepithelial component in, 92
 laryngeal mucosa, 38, 177
 nasal, 89
 nasopharyngeal, 36
 normal, 84
 oral, 17
 angiosarcoma of, 27
 oropharyngeal, 84
 paranasal sinus, 148
 pharyngeal, 84–5, 152
 respiratory, 140
 sinonasal, 128, 147
 sinonasal tract, 114
 sinonasal tract mucosa, 114
 squamous epithelium of, 112
 submucosa, 12–13, 134
 mucosal leishmaniasis (ML), 4, 6
 histological features of, 4
 tests to evaluate, 5–6
 mucous cells, 53
 multifocal nodular oncocytic hyperplasia (MNOH), 67–8
 multilayered epithelium, 119
 multinodular architecture, 47, 78
 multinucleated cells, 162
 multinucleated giant cells, 162
 Multiphenotypic Sinonasal Carcinoma, 110
 MYB gene rearrangement, 110–11
 mycobacterial infection, 6
 myeloid sarcoma (MS), 168–9
 myeloperoxidase, 168
 myoepithelial carcinoma (MC), 49–51, 70, 93
 sinonasal anaplastic myoepithelial carcinoma, 95–6
 myoepithelial cells, 29, 56, 60, 112–13
 PA with cytologic atypia of myoepithelial cells, 60–1
 myoepithelial differentiation, 111
 myoepithelial markers, 95
 myoepithelial neoplasms, 35
 myoepithelial proliferation, 112
 myoepithelioma, 35, 50
 myofibroblastic sarcoma, 79
 myofibroma of oral cavity, 78–9
 myofibromatosis, 79
 myogenin, 74, 76, 100
 positivity, 101, 103–4
 myogenin immunoreactivity, 77
 myopericytoma, 79
 myxochondroid matrix, 32
 myxoid matrix, 60, 128, 130
 myxoid stroma, 34, 112
- NAB2-STAT6 fusion gene, 137
 naris, 132
 nasal bleeding, 97, 112
 nasal cavity, 101, 103, 130
 bulging in, 116
 lined by ciliated respiratory type epithelium, 119
 lymphoepithelial-like carcinoma involving, 109
 sclerosing polycystic adenosis of, 121
 seromucinous glands of, 120
 nasal mucosa, 103, 128
 nasal (fibro)myxoma, 130–1
 nasal septum, 103, 110, 112, 141
 PA of, 112–13
 polypoid lesion of, 120
 posterior aspect of, 121
 nasolabial cyst (NLC), 149
 nasopharyngeal angiofibroma, 132, 137, 151
 nasopharyngeal lymphatic tissue, 36
 nasopharyngeal mucosa, 36
 nasopharyngeal oncocytic metaplasia, 37
 nasopharyngeal salivary gland anlage tumor, 123–4
 nasopharyngeal tumor, 123–4
 nasopharynx, 103, 123, 130, 132
 oncocytic metaplasia of, 36–7
 surface epithelium of, 123
 teratomas in, 124
 natural killer (NK) T-cell lymphoma, nasal type, 5, 89–90
 necrosis, 50–1, 74, 106
 areas of, 4–5
 comedo-like, 110
 focal areas of, 95
 geographic, 91
 necrotic debris, 1
 necrotic degenerated keratinocytes, 8–9
 necrotizing vasculitis of medium-sized vessels, 6
 necrotizing sialometaplasia, 19
 atypia and, 19
 mucoepidermoid carcinoma and, 19
 squamous cell carcinoma and, 19
 neoplastic cells, 22, 27, 38, 130
 arranged around thin-walled vessels, 78
 binucleated, 175
 CD10, 69
 cuboidal, 170
 in glomangiopericytoma, 137
 HHV8 in, 28
 immunoblasts and, 86
 large, 76, 86
 large with moderate cytoplasm, 183
 lymphoid infiltrate and, 65
 medium sized, 89
 multinucleated giant, 60
 nested arrangement, 95
 nuclear enlargement, 141
 pan-cytokeratins in, 65
 with plasmacytic differentiation, 86
 pleomorphism, 116
 plump spindle shape, 78–9
 polygonal, 108
 positive for S100 protein, 34

- with scant cytoplasm, 81–2, 99, 104, 183
 spindled, 138
 undifferentiated cells with uniform nuclear features, 81–2
 uniform in appearance, 94, 118
 uniform nuclei, 170
 neoplastic proliferation, 90
 neoplastic squamous epithelium, 21
 nephrectomy, 70
 nervous tissue, 102
 neural markers, 109
 neuroendocrine carcinomas, 92, 184
 metastatic, 160–1
 salivary gland, 66
 neuroendocrine cells, 72–3
 neuroendocrine differentiation, 94, 184
 neuroendocrine markers, 103
 neuroendocrine tumors, 76–7
 neuroepithelium, 124
 neurofibroma, 131
 neurofibromatosis type 2, 140
 neurofilament marker, 183
 neuroglial heterotopia, 172
 neuroglial tissue, 157
 neuronal cells, 172
 neutrophils, 16–17, 181
 NHL. *See* non-Hodgkin lymphoma
 NK. *See* natural killer
 NLC. *See* nasolabial cyst
 nodal metastases, 39–40
 nodular fasciitis, 79, 128–9
 non-Hodgkin lymphoma (NHL), 88
 non-keratinizing squamous cell metaplasia, 54
 non-septated fungal pseudohyphae, 179
 normal B lymphocytes, 86
 normal respiratory epithelium, 36
NTRK3 gene, 47
 nuclear atypia, 43, 170
 nuclear enlargement, 141
 nuclear hyperchromasia, 116
 nuclear pleomorphism, 117, 134, 160
 NUT carcinoma, 103, 109
 odontogenesis, 114
 odontogenic cysts, 148
 odontogenic epithelium, 14–15, 116
 odontogenic myxomas, 130
 odyphagia, 36
 olfactory neuroblastoma (ON), 77, 92, 95–9, 102, 105
 clinical suspicion of, 108
 high-grade, 108
 OLP. *See* oral lichen planus
 ON. *See* olfactory neuroblastoma
 oncocytic cells, 67
 oncocytic hyperplasia, 68, 70
 oncocytic metaplasia, 36–7, 68
 oncocytoma, 68, 70, 74
 OPSCC. *See* oropharyngeal squamous cell carcinoma
 optic nerve, 103
 oral cavity, 78–9, 86
 oral lichen planus (OLP), 8–9
 clinico-pathological correlation for, 9
 common sites of, 8
 oral lichenoid contact reactions and, 8–9
 oral lichenoid drug reactions and, 8–9
 remission rate of, 8
 oral lichenoid contact reactions, 8–9
 oral lichenoid drug reactions, 8–9
 oral mucosa, 17
 angiosarcoma of, 27
 oral precancerous lesions, 10
 oral soft tissues, 79
 oral ulcers, 1–2
 oropharyngeal lesions, 22
 oropharyngeal space, 81
 oropharyngeal squamous cell carcinoma (OPSCC), 40
 oropharyngeal wall, 84
 oropharynx, 22, 84, 152
 ossification, 164, 175
 osteochondroma of tongue, 31
 osteosarcoma, 33
 osteosarcoma-like stroma, 177
 otalgia, 36–7
 p16, 23–4, 38, 40, 108, 110
 p40, 25–6
 p63, 25, 32, 34, 43, 49–50
 immunoreactivity, 93–4
 positive for, 95–6
 squamous differentiation and, 26
 PA. *See* pleomorphic adenoma
 palate, 19, 56
 palatine tonsil, 27, 81, 151
 pale cytoplasm, 168
 pancytokeratin, 29, 32, 65, 72, 76, 95
 diffuse positivity for, 99
 negativity for, 161
 positive for, 95–6
 papillary fronds, 145
 papillary squamous cell carcinoma (PSCC), 22
 HPV and, 22
 keratinizing type of, 22
 non-keratinizing type of, 22
 squamous cell carcinoma and, 22
 verrucous carcinoma and, 22
 papilloma, 145
 papillomatosis, 179
 paraganglioma, 74
 parakeratinization, 21–2
 parakeratosis, 179
 parakeratotic epithelium, 179
 paranasal sinus mucosa, 148
 parotid gland, 41–2, 45, 47, 95, 121
 carcinoma ex-pleomorphic adenoma of, 58–9
 clear cell myoepithelial carcinoma of, 49–51
 cysts, 55
 metaplastic WT of, 54
 metastatic clear cell renal cell carcinoma of parotid gland, 70–1
 multifocal nodular oncocytic hyperplasia of, 67–8
 normally structured, 67
 pleomorphic adenoma in, 49
 recurrent pleomorphic adenoma of, 56–7
 residual, 56
 salivary tissue of, 69
 small cell neuroendocrine carcinoma of, 62–3
 tumors, 165
 PAX3, rearrangements of, 139
 PAX8, 70
 PAX-FOXO1 translocations, 77
 PCR. *See* polymerase chain reaction
 perichondrium, 166
 periodic acid–Schiff (PAS), 16, 118
 PAS diastase staining, 52–3
 PAS positive cytoplasmic glycogen, 67
 peripheral nerve sheath tumors, 35, 77, 135
 pharyngeal mucosa, 84–5, 152
 pharyngo-epiglottal plicae, 173
 PL. *See* plasmablastic lymphoma
PLG1 rearrangements, 35
 plasma cells, 16–18, 28, 89, 168
 dense infiltration of lamina propria, 17
 infiltrate of, 173, 181
 mature, 84–5
 plasma cell rich reactive infiltrates, 84
 plasmablastic lymphoma (PL), 84, 86–8
 plasmacytic differentiation, 86
 plasmacytoid cells, 93
 pleomorphic adenoma (PA), 29, 32, 35, 60, 70. *See also* Carcinoma ex pleomorphic adenoma
 with cytologic atypia of myoepithelial cells, 60–1
 diagnosis of, 33
 invasion in carcinoma ex-PA, 59
 metastasizing, 56–7
 of minor salivary glands, 31
 of nasal septum, 112–13
 in parotid gland, 49
 with predominantly tubular architecture, 58
 recurrent, 56
 residual, 59
 sinonasal PAs, 112–13
 of supposed submandibular origin, 33
 typical, 58
 pluripotent mesenchymal cells, 31
 polymerase chain reaction (PCR), 4–6
 polyp fragments, 106
 polypoid lesion, 29, 120, 173
 polyposis, 106
 poorly differentiated carcinoma with basaloid morphology, 93–4
 posterior choanae, 123
 postoperative maxillary cyst, 147–8
 pre-auricular swelling, 164–5
 preoperative imaging, 32
 primary intra nodal mucoepidermoid carcinoma, 53
 primary sinonasal intestinal type adenocarcinoma, 127
 primitive mesenchymal cells, 101
 primitive neuroectodermal tumor, 100
 primitive round cells, 101–2
 proliferating chondrocytes, 164
 proliferative endarteritis, 17–18
 proliferative verrucous hyperplasia, 10
 proliferative verrucous leukoplakia, 10
 prominent nucleoli, 106
 prostate carcinomas, 70
 proteinaceous fluid, 151
 PSCC. *See* papillary squamous cell carcinoma
 pseudoepitheliomatous hyperplasia, 13, 15
 pseudorosettes, 98
 pseudosarcomatous soft tissue lesion, 128
 pseudovascular spaces, 25
 pseudovascular structures, 173
 pterygomaxillary space, 132
 ptosis, 127
 pulmonary small cell carcinoma, 63
 pyogenic granuloma, 28
 R172, 108
 radiation-induced oral angiosarcoma, 27
 RCC. *See* renal cell carcinoma

Index

- REAH. *See* respiratory epithelial adenomatoid hamartoma
- recurrent pleomorphic adenoma, 56–7
- renal cell carcinoma (RCC)
 history of nephrectomy for, 70
 metastasis of, 70
 metastatic renal cell carcinoma, 70
 renal cell carcinoma antigen, 67
- respiratory epithelial adenomatoid hamartoma (REAH), 118–21
- respiratory epithelium, 103
- respiratory mucosa, 140
- respiratory type epithelium, 119, 128
- retrobulbar intraconal fat compartment, 103
- rhabdoid cells, 93
- rhabdomyoblastic differentiation, 101, 105
 focal, 139
- rhabdomyoma of adult type, 74
- rhabdomyosarcoma, 74, 100, 103, 106
 alveolar, 77, 103–5
 embryonal, 76–7, 97, 131
 sinonasal, 103
- rheumatoid arthritis, 4
- rhinorrhea, 114
- rhinoscleroma, 6
- rod-shaped cytoplasmic crystals, 74
- round cell sarcomas, 103
- round cells
 with high nuclear-to-cytoplasm ratio, 97
 with scant cytoplasm, 72
 sinonasal malignancies with high grade round cell morphology, 108
 uniform population of, 98
RREB1-MKL2 fusion gene, 35
- S100 protein, 14, 35, 43, 45, 49, 72, 76, 91
 negative, 103, 123
 positivity, 110
 diffuse, 138, 142
 for neoplastic cells, 34
 tumors negative for, 14
 tumor cells positive for, 50, 95–6
- SA. *See* sinonasal ameloblastoma
- salivary duct carcinoma, 46
- salivary gland, 63
 ischemia of tissue of, 19
 major, 113
 malignancies of, 58
 mammary analogue secretory carcinoma of, 46
 metastases to, 70
 minor, 29, 56, 95, 112, 121
- pleomorphic adenoma of, 31
- nasopharyngeal salivary gland anlage tumor, 123–4
- nasopharyngeal tumor and, 123–4
- neuroendocrine carcinomas, 66
- primary malignant salivary gland tumors, 68
- primary tumors of, 70
- sebaceous differentiation and, 43–4
- secondary tumors of, 70
 tumors, 29, 32
- salivary neoplasms, 49–51
- SC. *See* synovial chondromatosis
- scanty pale cytoplasm, 89
- SCC. *See* surgical ciliated cyst
- SCEC. *See* sinonasal neuroendocrine carcinoma
- Schneiderian membrane, 125
- Schwann cell neoplasms, 139
- Schwann cell tumors, 128
- Schwannoma, 138, 140–2
- sclerosing adenosis, 121
- sclerosing paraganglioma of carotid body, 160–1
- sclerosing polycystic adenosis of nasal cavity, 121
- sebaceous carcinoma, 44
- sebaceous differentiation, 43–4
- serology, 17
- seromucinous glands, 24, 120
- seromucinous glandular hamartoma, 119
- seromucinous hamartoma (SH), 118, 120
- sexual abuse, 17
- sexually transmitted infections, 17
- SH. *See* seromucinous hamartoma
- sinonasal ameloblastoma (SA), plexiform type, 114
- sinonasal anaplastic myoepithelial carcinoma, 95–6
- sinonasal benign conditions, 118
- sinonasal cavity, 86
- sinonasal glomangiopericytoma, 128–9, 134–5, 137
- sinonasal hemangiopericytoma, 132
- sinonasal high grade carcinomas, 98, 111
- sinonasal inflammatory polyp, 106
- sinonasal lesions, 22
- sinonasal malignant neoplasms, 91
- sinonasal melanoma, 91–2
- sinonasal mucosa, 128, 147
- sinonasal myxoma, 130
- sinonasal neuroendocrine carcinoma (SCEC), 99–100
- sinonasal neuroendocrine malignancies, 94
- sinonasal papilloma, 143, 145
 inverted type, 119, 145
 poorly differentiated squamous cell carcinoma arising in, 145
- sinonasal PAs, 112–13
- sinonasal rhabdomyosarcoma, 103
- sinonasal smooth muscle tumors, 135
- sinonasal solitary fibrous tumor, 136–7
- sinonasal surface mucosal epithelium, 114
- sinonasal teratocarcinosarcoma, 101–2
- sinonasal tract malignancies, 93
- sinonasal tract mucosa, 114
- sinonasal undifferentiated carcinoma (SNUC), 95, 97, 100, 103, 108–9
- sinonasal verrucous carcinoma, 143
- sinonasal-type hemangiopericytoma, 134–5
- sinusitis, 114
- small cell neuroendocrine carcinoma, 92, 97–8, 109
 of parotid gland, 62–3
- small cell neuroendocrine tumors, 62
- SMARCB1 (INI-1)-deficient carcinoma, 109
- SMARCB1 (INI-1)-deficient sinonasal carcinoma, 93–4
- SMARCB1-deficient carcinoma, 103
- smooth muscle actin, 34, 134
 alpha, 78–9
 positive, 95, 123
- smooth muscle cells, 155
- smooth muscle heavy chain, 95
- SNUC. *See* sinonasal undifferentiated carcinoma
- solid adenoid cystic carcinoma, 109
- solitary fibrous tumor, 128
- solitary plasmacytoma, 84–5
- sore throat, 81, 151
- SOX10, 41, 72
- sphenoid, 127
- spindle cell carcinoma, 82
 laryngeal spindle cell carcinoma with granulation tissue-like morphology, 181–2
- of larynx with osteosarcoma-like stroma, 177
- spindle cell squamous cell carcinoma, 106
- spindle-cell melanoma and, 92
- spindle cell myoepithelioma, 82
- spindle cells, 27, 128
 bland, 138
 cellular proliferation of ovoid to, 32–3
 with distinctive cytoplasmic borders, 28
 with eosinophilic cytoplasm, 155
 in fascicular pattern with focal myxoid areas, 81–2
 fibroblast-like, 128
 immunohistochemical examination of, 123
 lipoma, 29
 mesenchymal neoplasms, 132
 moderate atypia, 173
 monomorphic, 173
 nodules, 123
 proliferation, 141
 with scant eosinophilic cytoplasm, 140–1
 spindle-cell melanoma, 92
 uniform subepithelial proliferation of, 128
- squamous cell carcinoma, 13, 40, 54, 70, 102, 143. *See also* acantholytic squamous cell carcinoma; papillary squamous cell carcinoma
- basaloid, 111, 114
- conventional, 10, 23
 acantholytic squamous cell carcinoma and, 26
 moderately differentiated, 23
 seromucinous glands and, 24
- keratinizing, 23–4, 38
- laryngeal, 39–40
- necrotizing sialometaplasia and, 19
- non-keratinizing, 92
- poorly differentiated, 95, 103
- poorly differentiated squamous cell carcinoma arising in sinonasal papilloma, 145
- spindle cell, 106
- verrucous, 10
 with verrucous features, 22
- squamous differentiation, 94, 111–12
- squamous epithelial lining, 150
- squamous epithelium, 12, 14, 40, 55, 152, 155
 with clear cytoplasm, 101
 dysplastic, 25
 immature, 102
 intact, 151
 islands of, 19
 keratinizing, 143

Index

- mature, 150
 lining, 159
 mature, 155
 metaplastic, 54
 of mucosa, 112
 neoplastic, 21
 non-keratinizing, 144
 polypoid lesion covered by, 29
 pseudoepitheliomatous
 hyperplasia of, 15
 superficial flattened, 14
 surface, 110, 114
 squamous metaplasia, 112–13
 with keratinization, 112
 squamous metaplasia with
 keratinization, 112
 squamous papilloma, 151
 squamous surface dysplasia, 94
 SS. *See* tonsillar synovial sarcoma
 STAT6, 136–7
 stellate reticulum, 114
 stroma reaction, 45
 stromal-mesenchymal nodules,
 123
 subcutaneous fat, 56
 sub-epithelial proliferation, 130
 subepithelial stroma, 16, 153
 subepithelial tissue, 84
 sublingual gland, 70
 submandibular gland, 32, 52–3,
 56, 70, 95, 121
 submandibular lymph nodes, 17
 submandibular triangle, 52
 submucosa, 12–13, 134
 subnuclear cytoplasmic
 vacuolization, 114
 superficial flattened squamous
 epithelium, 14
 supra basal mitotic figure, 10
 supraglottic space, 173
 surface epithelium, 10, 25, 91, 94,
 136
 of nasopharynx, 123
 verruciform hyperplasia of, 10
 surface lining, 166
 surface nasopharyngeal
 epithelium, 123
 surgical ciliated cyst (SCC),
 147–8
 synaptophysin, 72, 97–8
 diffuse positivity for, 99
 negative, 103
 positivity for, 161
 synchronous oropharyngeal
 HPV-related carcinoma,
 39–40
 synovial chondromatosis (SC),
 164–5
 synovial sarcoma, 124
 synovium, 164
 syphilis, 6, 16
 primary, 17
 secondary, 17
 oral lesions and, 17
 typical sites for, 17
 sexual abuse and, 17
 on tongue, 17
 SYT gene, 81–2
 T cells
 exuberant T cell reaction, 5
 markers, 88
 peripheral T-cell lymphomas, 5
 receptor gene rearrangement,
 88
 T. pallidum, 16
 temporomandibular joint, 162–5
 tenosynovial giant cell tumor
 (TGCT), 162–3
 teratocarcinosarcoma, 98
 teratoid tumor, 150
 teratomas, 14, 124, 150, 156–7
 TGCT. *See* tenosynovial giant
 cell tumor
 thyroid transcription factor 1
 (TTF1), 72–3, 171
 TIA1, 90
 TLE1, 82
 TNF- α antagonists, 4
 T-oligoclonal pattern, 86
 tongue, 27, 79
 chondroid lipoma and, 29
 intrinsic muscles of, 31
 myxoid neoplasms of,
 34–5
 osteochondroma of, 31
 soft tissues of, 31
 subepithelial tissue of, 74
 syphilis on, 17
 ulcers on, 1
 tonsillar synovial sarcoma (SS),
 82
 tonsils
 crypts of tonsillar tissue, 21–2
 hypertrophic, 21
 palatine tonsil, 27
 TP53, 125
 tracheotomy, 81
 transitional epithelium, 145, 152
 transthyretin, 152
Treponema pallidum, 16–17
 trichoepitheliomas, 42
 TTF1. *See* thyroid transcription
 factor 1
 tubulo-papillary architecture,
 118
 tubulo-papillary growth pattern,
 118
 tumor suppressor gene
 alterations, 119
 ultrasound examination, 52
 underlying stroma, 12–13
 undifferentiated carcinomas,
 102–3
 undifferentiated cells, 108
 undifferentiated round cells,
 95–6, 102
 unencapsulated cystic lesion,
 52–3
 uniform bland fibroblast-like
 cells, 132
 vascular markers, 28
 vascular tumors, 132
 vasoformative foci, 28
 verruciform hyperplasia,
 10
 verrucous carcinoma, 22,
 143
 verrucous carcinoma of
 maxillary sinus, 143–4
 VHL gene mutation, 170
 vimentin, 14, 49, 123
 vocal cords, 38
 von Hippel-Lindau disease,
 170
 Waldeyer's ring, 66
 Warthin's tumor (WT), 37, 53–4
 Wegener's granulomatosis, 90
 WHO Classification of Head and
 Neck Tumours, 184
 WT. *See* Warthin's tumor
 WT1, 76
 xanthoma cells, 162
 Zuckerkandl, Emile,
 149
 zygomatic region, 116